Search

Displaying results 1081 - 1090 of 4539 in total
  1. Drug

    Metronidazole

    go.drugbank.com/drugs/DB00916
    ApprovedInvestigational

    Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic inf...

    Mixtures: METRONIDAZOL / NISTATINA 500MG/100.000 UI
  2. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]

  3. Drug

    p-tert-Butylphenol-formaldehyde resin (low molecular weight)

    go.drugbank.com/drugs/DB14190
    Approved

    p-tert-Butylphenol-formaldehyde resin is a widely used adhesive chemical used in a wide variety of commercially available products and a known dermatological sensitizer and allergen . Sensitivity to p-tert-Butylphenol-formaldehyde resin ...

  4. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood.

  5. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat is marketed by Novartis under the brand name Farydak. … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

  6. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.

  7. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  8. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

  9. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … [A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-

  10. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. … The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.